PFE vs V: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and Visa Inc. โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-05.
Pfizer Inc. ยท Healthcare
$26.33
+28.6% upside to fair value
Grade B
VS
Visa Inc. ยท Financial Services
$304.36
+45.0% upside to fair value
High Conviction Grade A-
QuantHub Verdict
V has more upside to fair value (+45.0%). PFE trades at a lower forward P/E (19.3x). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric PFE V
Current Price $26.33 $304.36
Fair Value Estimate $33.85 $441.32
Upside to Fair Value +28.6% +45.0%
Market Cap $149.8B $586.8B
Forward P/E 19.3x 23.7x
EV / EBITDA 12.9x 22.3x
Price / Sales 2.4x 14.2x
Price / FCF 16.5x 25.6x
Revenue Growth YoY -1.2% +11.3%
Gross Margin 70.3% 81.08%
Operating Margin 24.7% 59.18%
Return on Equity 8.7% 54.22%
Dividend Yield 0% 0.83%
FCF Yield 6.06% 3.91%
Analyst Consensus Hold Strong Buy
Investment Thesis
PFE โ€” Pfizer Inc.
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating maโ€ฆ
V โ€” Visa Inc.
Visa is the world's dominant payment network with $40B in net revenue (FY2025), 50%+ net margins, and a capital-light toll-booth model processing $14.2T in annual payment volume across 257.5B transactions. The business compounds at 10-12% revenue CAGR with operating leverage pushing EPS growth to 12-15% over a cycle, funded by $21.6B in annual free cash flow against only $1.5B in capex. At 28.0x โ€ฆ
Accumulation Zones
Metric PFE V
Zone Low $25.39 $330.99
Zone High $28.77 $375.12
In Buy Zone? Yes Yes
โ† PFE Research    V Research โ†’    All Research